Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →This statewide retrospective claims-registry cohort found documented fertility preservation, psychosocial/mental health care, and palliative care in fewer than half of AYAs with cancer, with disparities by age, rurality, race, and ethnicity.
The evidence identifies gaps and inequities in supportive-care delivery; it supports the inference that system- and provider-level interventions targeting fertility preservation, mental health, and palliative-care integration could improve guideline concordance, but the study does not test an intervention or demonstrate improved clinical outcomes.
This multicenter study developed and psychometrically validated a 20-item financial-toxicity measure in 200 adult cancer patients and 148 caregivers of pediatric patients, demonstrating strong reliability, internal structure, and convergent validity in a middle-income Latin American context.
The evidence supports TF-Col as a contextually relevant assessment tool, while it remains an inference—not tested here—that routine screening could identify families needing financial or supportive interventions and thereby improve adherence, quality of life, or cancer outcomes.
This position paper describes persistent neuropsychological late effects in pediatric oncology, identifies a substantial care gap, and calls for longitudinal monitoring, rehabilitation, standardized transition processes, reimbursement, and nationwide access to specialized services.
The record supports the need for structured neuropsychological care but does not test its efficacy; it is reasonable to hypothesize that early, hypothesis-driven assessment followed by tailored interventions and long-term monitoring could improve functioning, autonomy, quality of life, and participation.
In a retrospective NIH cohort of 1,025 patients, including 118 children, extreme eosinophilia was rarely attributable to parasitic infection, while serum IgE did not meaningfully distinguish parasitic from non-parasitic causes.
The evidence supports peak absolute eosinophil count as a potential diagnostic-triage marker; by inference, recognizing extreme eosinophilia as unlikely to be parasitic could accelerate evaluation for malignancy or hypereosinophilic syndromes, but the record does not demonstrate improved treatment selection or clinical outcomes.
In a SEER cohort of 19,051 adults aged 18–64 with glioblastoma, lower county-level income was associated with worse overall survival, while receipt of surgical resection mediated little of the disparity and the residual association was potentially susceptible to unmeasured confounding.
Evidence: equalizing receipt of surgical resection alone was estimated to be insufficient to eliminate the income-associated survival gap. Inference: identifying and intervening on nonsurgical factors—potentially including access to adjuvant therapy, supportive care, treatment continuity, or other unmeasured clinical determinants—could offer a more effective route to reducing disparities, but these specific mediators were not evaluated in the supplied record.
This report describes a 10-year-old boy with BRAF V600E-mutant anaplastic pleomorphic xanthoastrocytoma treated with combined BRAF/MEK inhibition, in whom posttherapy [18F]FDOPA PET provided metabolic information that preceded and complemented conventional imaging.
The case provides preliminary evidence that [18F]FDOPA PET may help monitor targeted therapy in BRAF V600E-mutant pediatric APXA; it remains an inference—not established by this record—that earlier metabolic changes could improve treatment-response assessment or therapeutic decision-making.
This comprehensive review of 21 geographically diverse real-world studies reports that quadrivalent or nonavalent HPV vaccination in males is associated with reductions in oral, penile, and anal HPV infection and anogenital warts, with greater effectiveness in younger vaccine recipients and additional population benefit from gender-neutral vaccination programs.
The supplied evidence supports HPV vaccination as a practical prevention strategy for male HPV infection and anogenital warts; it is reasonable but not directly demonstrated here to hypothesize that adolescent gender-neutral vaccination could reduce subsequent HPV-associated precancers and cancers, because cancer-specific effectiveness results are not provided.
This report describes an 18-year-old male with primary left atrial cardiac sarcoma, intracranial metastases, embolic cerebral infarcts, rapid postoperative brain-lesion recurrence, and a favorable six-week imaging response after repeated resections, Gamma Knife radiosurgery, and chemotherapy.
The case provides evidence that aggressive multimodal management can achieve short-term intracranial disease control in one pediatric patient; it supports, but cannot establish, the hypothesis that repeat resection combined with focused radiosurgery and systemic chemotherapy may benefit selected patients with CNS involvement from cardiac sarcoma.
This cross-sectional analysis of ClinicalTrials.gov identified 1,863 monoclonal-antibody trials allowing pediatric enrollment and found limited pediatric-only enrollment, marked geographic and disease-area inequities, frequent accrual-related termination, and substantial results-reporting and document-transparency gaps.
The evidence shows structural gaps in pediatric mAb trial access and transparency; by inference, targeted investment in geographically inclusive recruitment, pediatric-specific trial infrastructure, and disclosure compliance could improve mAb development and eventual treatment access, although the record does not test this strategy or establish benefit for pediatric cancer patients.
In an observational comparison of 89 cirrhotic patients with hepatic cancer, camrelizumab plus radiofrequency ablation was associated with a higher reported response rate and favorable biomarker changes versus ablation alone, without a significant difference in overall adverse-reaction incidence.
The record provides preliminary human evidence that adding camrelizumab to radiofrequency ablation may improve treatment response in cirrhosis-associated hepatic cancer; whether immune modulation causes this benefit, improves durable clinical outcomes, or applies to pediatric patients remains an inference requiring controlled prospective testing.
This retrospective single-center study of 24 children with hepatoblastoma treated over 17 years reports 75% overall survival, with better survival in PRETEXT 1–2 than PRETEXT 3–4 disease and two postoperative relapses among 23 treated patients.
The study provides observational evidence that multimodal management incorporating preoperative chemotherapy and surgery can achieve durable survival in a tertiary-center setting; it supports, but does not prove, the hypothesis that earlier PRETEXT stage and complete resection with negative margins help identify children most likely to benefit from this approach.
This record reviews Wilms tumor biology, risk stratification, and multimodal treatment, contrasting upfront nephrectomy with preoperative chemotherapy and highlighting nephron-sparing surgery, intensified treatment for high-risk disease, and trials seeking toxicity reduction.
The supplied record supports current risk-adapted, multimodal management of Wilms tumor; it is reasonable but inferential to hypothesize that biomarker-refined treatment selection and de-escalation trials could preserve cure rates while reducing toxicity, because no trial outcomes or comparative data are provided.
